I
n the week before Christmas, some 6,000 genetically modified (GM) mosquitoes were deliberately introduced to an uninhabited forest in Malaysia. The move took many local people and international observers by surprise. They had thought that the trial, which aims to investigate how long the modified insects live and how far they can fly, had been postponed.
The mix-up was down to the media confusing the trial with a second planned experiment, due to take place in a populated area later this year. But it adds to a growing sense of unease among some in the field about the way in which the public are consulted and notified about such experiments. The Malaysian trial, developed as an approach to controlling dengue fever by the British biotech company Oxitec, based in Oxford, followed the release of 3.3 million of the firm's GM insects in separate tests in the Cayman Islands in 2009 and 2010. There is no suggestion that any of the releases was unsafe, or contravened any law. In line with Malaysia's biosafety rules and the Cayman Islands' draft rules, permits were issued after the relevant national authorities performed risk assessments.
But scientists and local people alike have taken issue with the manner in which the public engagement was handled, as well as the choice of the Cayman Islands, where, unlike Malaysia, biosafety considerations are not well developed. Even specialist researchers in the GM mosquito field -hardly a sprawling sector -say that they first heard about Oxitec's experiments in the Cayman Islands only when the company announced the results at an academic conference in November.
If the release of GM organisms is handled badly, it could generate an unnecessary and unhelpful climate of suspicion. One problem is that there is no standard laboratory procedure when it comes to informing the public of such experiments. Moreover, is merely informing them sufficient? Given the farce over the use of GM crops in Europe, early buy-in and support from local communities would be a good way to deflect unfounded fears that could surface in the future, particularly given that early findings are promising. (Oxitec says the release of the GM mosquitoes in the Cayman Islands study successfully reduced the wild dengue-carrying population by about 80%.) But researchers who work on GM insects say that they are unsure how much public engagement is enough and who has responsibility for it.
Transparency is essential. The Malaysian authorities went to some lengths to inform people that the trials were going ahead, holding open forums and briefing the media, which gave the experiments wide coverage. The resulting discussion highlighted concerns. It also seeded an appetite for more information, which seems to have been responsible for the subsequent confusion over the trial's timing. By contrast, efforts by the Cayman Island authorities seem to have amounted to not much more than producing little-reported leaflets and a video, posted on YouTube and broadcast on television, which failed to say that the mosquitoes were genetically modified -the main concern of critics.
A fair share
The Hungarian government needs to up its stake in the nation's scientific future. F or almost 20 years, the Collegium Budapest has stood as a symbol of a new era of science in central and eastern Europe. Some 700 scholars from 40 countries have spent time in its rarefied intellectual atmosphere -an esteemed institute for advanced study -where, free from teaching and administrative burdens, they have produced hundreds of papers and books in fields ranging from economics to political sciences, theoretical biology and the humanities. Given its widely recognized success, why does the collegium now face threats to its survival?
Researchers, both in the public and private sector, should do more to ensure that the relevant authorities make the relevant facts available, or do so themselves. It is they, not the authorities, after all, that will probably be the focus of protests and complaints if public engagement is handled badly. With this in mind, scientists at the University of California, Irvine, have developed and published a detailed and ambitious framework to engage the public in global-health initiatives (J. V. Lavery et al. Trends Parasitol. 26, 279-283 ; 2010 ) -heavily based on their own experiences with GM mosquito research in Mexico.
In the absence of guidelines to help researchers to deal with local communities, the authors produced 12 of their own, which include rigorous site selection, to ensure that the purpose and goals of the research are made clear, and the use of focus groups and citizen councils to probe local opinions and to decide whether informed consent is necessary. Although many of the issues are common to such research, the decisions must be taken on a siteby-site basis, they say. The World Health Organization is also drawing up guidelines, which it says will help scientists to assess the social and cultural issues relating to their work.
Oxitec acknowledges that there are lessons to learn from its experiences. Best placed to judge the results of this are the people of Brazil, the planned site of the company's next experiment.
So far, GM mosquitoes and other insects have largely flown beneath the radar. That will change sooner or later. It is surely better that the scientists involved bring them to the public's attention, rather than have that attention thrust upon them by others. 
Best is yet to come
Ten years after the human genome was sequenced, its promise is still to be fulfilled. F ormer US president Bill Clinton called it the "most important, most wondrous map ever produced by humankind". To then UK prime minister Tony Blair, it was a "breakthrough that takes humankind across a frontier and into a new era". His science minister David Sainsbury said: "We now have the possibility of achieving all we ever hoped for from medicine. " When Nature published a 62-page article on 15 February 2001 titled 'Initial sequencing and analysis of the human genome' it is not difficult to see why the world got excited. Perhaps, even, a little overexcited. One of our editors, Henry Gee, penned a newspaper piece at the time that promised, by 2099, "genomics will allow us to alter entire organisms out of all recognition, to suit our needs and tastes … [and] will allow us to fashion the human form into any conceivable shape. We will have extra limbs, if we want them -maybe even wings to fly. "
As Eric Lander, director of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and the first author on that 2001 paper, writes on page 187 of this issue: "The human genome has had a certain tendency to incite passion and excess. " A decade on, Lander notes, the pattern continues, with "a front-page news story on the tenth anniversary of the announcement that chided genome scientists for not yet having cured most diseases". The 2001 sequence was always a milestone on the journey to better medical care, rather than a destination. The ten-year anniversary of the publication in Nature and Science of sequences prepared respectively by the international Human Genome Project and Celera Genomics, now of Alameda, California, provides another -as well as an opportunity to reflect on progress.
Some things have undoubtedly changed. Nature's Editorial page in the 15 February 2001 issue examined not the scientific and medical promise of the genome sequence, but the challenge of public access to information gathered by the commercial genomics sector. Acrimony over the differing public and private approaches has since faded; concerns over access to genomic data now centre on privacy issues.
Has medical progress been slower than was expected at the time? In an article on page 204, Eric Green and Mark Guyer of the US National Human Genome Research Institute in Bethesda, Maryland, offer an "updated vision" of the prospects for genomic medicine. "Significant change rarely comes quickly, " they write. "Although genomics has already begun to improve diagnostics and treatments in a few circumstances, profound improvements in the effectiveness of healthcare cannot realistically be expected for many years. " Research is not enough, they say, and new policies and practices as part of an expanded global effort are needed too.
The sequencing of the human genome was in many ways a triumph for technology as much as it was for science. That technology has continued to develop over the past decade, which Elaine Mardis of the Genome Center at Washington University in St Louis describes in an article starting on page 198 as a "remarkable sequencing technology explosion".
Massively parallel sequencing technology allows questions to be asked and answered with "unprecedented speed and resolution", she says. "The continuing upward trajectory of sequencing technology development is enabling clinical applications that are aimed at improving medical diagnosis and treatment. " A useful example is the development of genome-wide association studies to probe the underlying genetic landscape of some common diseases.
More than a decade ago, Michael Dexter, then head of the UK Wellcome Trust, which took part in the Human Genome Project, branded the genome sequence as the outstanding achievement of human history, eclipsing the significance both of the Moon landings and of the invention of the wheel. It is too early for that history to be written. For the genome sequence to be a true success, we must yet ensure that greater achievements are built on it. ■ On one level, its problems are financial. The institute's international sponsors, including a number of western European governments, banks and private foundations, want the Hungarian government to bear much more of the collegium's annual cost, which runs to around €1.2 million (US$1.6 million). The Hungarian hosts currently contribute just €100,000 per year, which goes towards the costs of accommodation and salaries for a core staff of 30 or so visiting and permanent fellows. This is little more than it paid during the relatively lean early years after the institute opened in 1992. Given the country's expanded economic potential and its membership of the European Union (EU) since 2004 -of which it currently holds the presidency -the German government and other sponsors have asked Hungary to boost its share to about half the annual costs. If Hungary does not find the money, foreign sponsors say that they will withdraw their support.
But €600,000 is apparently more than Hungary is willing to pay for an intellectual enclave of international repute, housed in the former city hall in Budapest's historic castle district, provided rent-free by the Hungarian Academy of Sciences.
Miklós Réthelyi, Hungary's minister for national resources (and science), promised last year to examine whether EU structural funds could be used to maintain the collegium. But in December, discussion of the issue was again postponed, adding to concerns that Hungary is no longer interested in keeping the institute alive. The collegium's assembly of members, which will discuss the collegium's future at a meeting in April, is beginning to lose hope.
Perhaps the Hungarian government would not be particularly sorry to lose this academic jewel. The collegium is also known as a haven of outspokenness, and some suspect that the output of some of its scholars is unwelcome in government circles. Hungarian economist János Kornai, for example, recently published a caustic analysis of current political tendencies in Hungary.
If the collegium is forced to close, much will be lost. Institutes for advanced study are a vital element of modern science systems -a niche in the bustle of academic routine where researchers can find the time to elaborate on thoughts and concepts, and exchange ideas with colleagues from other disciplines. In Hungary, the Collegium Budapest brings an international flavour to Hungarian science. Senior figures from overseas are hard to find in its other universities and research institutes. The Hungarian government should have the courage to do the right thing and take on a fair share of the costs, even if it doesn't primarily serve current domestic needs. Doing so would help to counter the widespread impression -furthered by a new and restrictive media law, and by a badly handled row over alleged misuse of research grants by a group of philosophers with the Academy of Sciences -that Hungary's leadership is drifting towards autocracy and that critical discourse is being stifled. The political and societal challenges ahead certainly demand 'honesty and trust' -the title of a Collegium Budapest project on the post-socialist transformation process. Budapest, with its rich scholarly tradition, has been an ideal place for people to study and reconcile diverging cultures of knowledge in a reshaped Europe. The changes under way in the Arab world may reshape East-West relations on a much larger scale. The Collegium Budapest would be a good place to begin to ponder what that might mean. ■ "The political and societal challenges ahead certainly demand honesty and trust."
